Movement Alert｜Novavax Falls 8.04% in Regular Trading, UBS Downgrade to Neutral Pressures Sentiment

Market Focus10-23

On October 23, Novavax fell 8.04% in Regular Trading, trading at $10.04 per share, with turnover of $49.73 million.

The clearest catalyst was a newly disclosed UBS rating downgrade to Neutral, which appears to have directly weighed on near-term risk appetite toward the stock.

As additional context, Bank of America earlier raised its price target to $8 from $7 while keeping an Underperform rating. Novavax had also reported second-quarter results above expectations, with EPS of $(0.32) versus an expected $(0.37) loss and revenue of $56.698 million versus expectations of $52.513 million, but that earnings beat was not enough to offset the more recent cautious analyst stance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment